Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group.

Dlugi AM, Miller JD, Knittle J

Fertility and sterility1 Sept 1990Cited by 176 (Europe PMC)

PMID2118858DOI10.1016/s0015-0282(16)53755-8PepBankPUB-02118858

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with endometriosis, leuprolide significantly improved dysmenorrhea versus placebo.
In plain wordsIn patients with endometriosis, leuprolide reduced menstrual pain more than placebo.
Peptide
Leuprolide
Outcome
DecreaseDysmenorrhea
Study
n = 52
Comparator
Placebo
Outcome group
Pain · Reproductive and sexual health
Studied dose
3.75 mgAs given in this study (human).
Source sentences
Summary
Dysmenorrhea, pelvic pain, and pelvic tenderness all responded significantly to LA treatment in comparison with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
The safety and efficacy of leuprolide acetate (LA) for depot suspension (Lupron depot; TAP Pharmaceuticals, North Chicago, IL), 3.75 mg versus placebo, in the treatment of pain associated with endometriosis was assessed in a randomized, double-blind, multicenter study involving 52 patients.
Report a problemFND-0211885801
02HumanRandomized controlled trialEfficacy outcome
In patients with endometriosis, leuprolide significantly improved pelvic pain versus placebo.
In plain wordsIn patients with endometriosis, leuprolide reduced pelvic pain more than placebo.
Peptide
Leuprolide
Outcome
DecreasePelvic pain
Study
n = 52
Comparator
Placebo
Outcome group
Pain · Reproductive and sexual health
Studied dose
3.75 mgAs given in this study (human).
Source sentences
Summary
Dysmenorrhea, pelvic pain, and pelvic tenderness all responded significantly to LA treatment in comparison with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
The safety and efficacy of leuprolide acetate (LA) for depot suspension (Lupron depot; TAP Pharmaceuticals, North Chicago, IL), 3.75 mg versus placebo, in the treatment of pain associated with endometriosis was assessed in a randomized, double-blind, multicenter study involving 52 patients.
Report a problemFND-0211885802
03HumanRandomized controlled trialEfficacy outcome
In patients with endometriosis, leuprolide significantly improved pelvic tenderness versus placebo.
In plain wordsIn patients with endometriosis, leuprolide reduced pelvic tenderness more than placebo.
Peptide
Leuprolide
Outcome
DecreasePelvic tenderness
Study
n = 52
Comparator
Placebo
Outcome group
Pain · Reproductive and sexual health
Studied dose
3.75 mgAs given in this study (human).
Source sentences
Summary
Dysmenorrhea, pelvic pain, and pelvic tenderness all responded significantly to LA treatment in comparison with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
The safety and efficacy of leuprolide acetate (LA) for depot suspension (Lupron depot; TAP Pharmaceuticals, North Chicago, IL), 3.75 mg versus placebo, in the treatment of pain associated with endometriosis was assessed in a randomized, double-blind, multicenter study involving 52 patients.
Report a problemFND-0211885803
04HumanRandomized controlled trialSafety outcome
In patients with endometriosis, vasodilatation occurred significantly more frequently with leuprolide than placebo.
In plain wordsIn patients with endometriosis, leuprolide caused more vasodilatation than placebo.
Peptide
Leuprolide
Outcome
IncreaseVasodilatation
Study
n = 52
Comparator
Placebo
Outcome group
Adverse events · Cardiovascular
Studied dose
3.75 mgAs given in this study (human).
Source sentences
Summary
The most common adverse event was vasodilatation, occurring significantly more frequently in the LA group.
1 context sentence(design, population, supporting numbers)
Summary · context
The safety and efficacy of leuprolide acetate (LA) for depot suspension (Lupron depot; TAP Pharmaceuticals, North Chicago, IL), 3.75 mg versus placebo, in the treatment of pain associated with endometriosis was assessed in a randomized, double-blind, multicenter study involving 52 patients.
Report a problemFND-0211885807
05HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, leuprolide suppressed menses in all treated patients.
In plain wordsIn patients with endometriosis, all leuprolide recipients stopped menstruating.
Peptide
Leuprolide
Outcome
DecreaseMenstrual suppression
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mgAs given in this study (human).
Source sentences
Summary
Menses were suppressed in all of the LA patients.
1 context sentence(design, population, supporting numbers)
Summary · context
The safety and efficacy of leuprolide acetate (LA) for depot suspension (Lupron depot; TAP Pharmaceuticals, North Chicago, IL), 3.75 mg versus placebo, in the treatment of pain associated with endometriosis was assessed in a randomized, double-blind, multicenter study involving 52 patients.
Report a problemFND-0211885804
06HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, estradiol decreased significantly to menopausal levels during leuprolide treatment.
In plain wordsIn patients with endometriosis, estradiol decreased to menopausal levels during leuprolide treatment.
Peptide
Leuprolide
Outcome
DecreaseEstradiol
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mgAs given in this study (human).
Source sentences
Summary
Estradiol decreased significantly to menopausal levels in the LA group.
1 context sentence(design, population, supporting numbers)
Summary · context
The safety and efficacy of leuprolide acetate (LA) for depot suspension (Lupron depot; TAP Pharmaceuticals, North Chicago, IL), 3.75 mg versus placebo, in the treatment of pain associated with endometriosis was assessed in a randomized, double-blind, multicenter study involving 52 patients.
Report a problemFND-0211885805
07HumanNon-randomized trialSafety outcome
In patients with endometriosis, laboratory parameters showed small to moderate changes that were not clinically significant.
In plain wordsIn patients with endometriosis, laboratory changes during leuprolide treatment were small to moderate and not clinically significant.
Peptide
Leuprolide
Outcome
Direction not reportedLaboratory parameters
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
3.75 mgAs given in this study (human).
Source sentences
Summary
There were small to moderate changes in a variety of laboratory parameters, but these were not clinically significant.
1 context sentence(design, population, supporting numbers)
Summary · context
The safety and efficacy of leuprolide acetate (LA) for depot suspension (Lupron depot; TAP Pharmaceuticals, North Chicago, IL), 3.75 mg versus placebo, in the treatment of pain associated with endometriosis was assessed in a randomized, double-blind, multicenter study involving 52 patients.
Report a problemFND-0211885806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.